当前位置:
X-MOL 学术
›
Am. J. Clin. Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
A Pilot Study of Preoperative Vandetanib on Markers of Proliferation and Apoptosis in Breast Cancer.
American Journal of Clinical Oncology ( IF 1.6 ) Pub Date : 2021-06-30 , DOI: 10.1097/coc.0000000000000845 Philip M Spanheimer 1 , Amani Bashir 2 , Allison W Lorenzen 3 , Anna C Beck 3 , Junlin Liao 3 , Ingrid M Lizarraga 3 , Lillian M Erdahl 3 , Sonia L Sugg 3 , Mark W Karwal 4 , Ronald J Weigel 3
American Journal of Clinical Oncology ( IF 1.6 ) Pub Date : 2021-06-30 , DOI: 10.1097/coc.0000000000000845 Philip M Spanheimer 1 , Amani Bashir 2 , Allison W Lorenzen 3 , Anna C Beck 3 , Junlin Liao 3 , Ingrid M Lizarraga 3 , Lillian M Erdahl 3 , Sonia L Sugg 3 , Mark W Karwal 4 , Ronald J Weigel 3
Affiliation
Preclinical data supports antitumor activity of tyrosine kinase inhibitor vandetanib with Ret as the therapeutic target in breast cancer. We investigated the effect of preoperative vandetanib on markers of proliferation and apoptosis in breast cancer.
中文翻译:
术前凡德他尼对乳腺癌增殖和凋亡标志物的初步研究。
临床前数据支持酪氨酸激酶抑制剂凡德他尼以 Ret 作为乳腺癌治疗靶点的抗肿瘤活性。我们研究了术前凡德他尼对乳腺癌增殖和凋亡标志物的影响。
更新日期:2021-07-02
中文翻译:
术前凡德他尼对乳腺癌增殖和凋亡标志物的初步研究。
临床前数据支持酪氨酸激酶抑制剂凡德他尼以 Ret 作为乳腺癌治疗靶点的抗肿瘤活性。我们研究了术前凡德他尼对乳腺癌增殖和凋亡标志物的影响。